Rhabdomyosarcoma (RMS) is a childhood soft tissue tumor with broad expression of markers that are typically found in skeletal muscle. Cavin-1 is a recently discovered protein actively cooperating with Caveolin-1 (Cav-1) in the morphogenesis of caveolae and whose role in cancer is drawing increasing attention. Using a combined in silico and in vitro analysis here we show that Cavin-1 is expressed in myogenic RMS tumors as well as in human and primary mouse RMS cultures, exhibiting a broad subcellular localization, ranging from nuclei and cytosol to plasma membrane. In particular, the coexpression and plasma membrane interaction between Cavin-1 and Cav-1 characterized the proliferation of human and mouse RMS cell cultures, while a downregulation of their expression levels was observed during the myogenic differentiation. Knockdown of Cavin-1 or Cav-1 in the human RD and RH30 cells led to impairment of cell proliferation and migration. Moreover, loss of Cavin-1 in RD cells impaired the anchorage-independent cell growth in soft agar. While the loss of Cavin-1 did not affect the Cav-1 protein levels in RMS cells, Cav-1 overexpression and knockdown triggered a rise or depletion of Cavin-1 protein levels in RD cells, respectively, in turn reflecting on increased or decreased cell proliferation, migration and anchorage-independent cell growth. Collectively, these data indicate that the interaction between Cavin-1 and Cav-1 underlies the cell growth and migration in myogenic tumors. Rhabdomyosarcoma (RMS) is a childhood soft tissue sarcoma exhibiting broad expression of skeletal muscle markers, 1-3 such as Pax7, MyoD, Myogenin, desmin and muscle-specific actin. 4,5 Cells of origin in RMS may be different muscular and non-muscular cell precursors, 6-8 such as muscle satellite cells (SCs), 9-11 and myoblasts 9,10,12-14 or adipocytes, 15 which are responsible of two major histological subtypes known as embryonal (ERMS) and alveolar (ARMS). The most common ERMS variant arises in children usually o5 years on distinct body sites, such as head, neck and genitourinary regions, while ARMS typically arises in the muscular limb extremities of adolescents and is characterized by poorer prognosis. 16 The genomic landscape causative of ERMS is characterized by a number of genetic lesions and/or somatic mutations that deliberately sustain the activity of different receptors, such as IGF1R, FGFR4 and Patched, 17-21 and related downstream pathways (i.e., RAS/ERK, PI3K/AKT and Sonic Hedgehog signaling). 11, 22 In addition, defects in tumor suppressors (i.e., p53), 23 cell cycle regulatory genes (i.e., N-Myc, Rb1) 21, 24 and structural proteins involved in muscular integrity (i.e., dystrophin, alpha-sarcoglycan and dysferlin) have been reported. [25] [26] [27] [28] [29] [30] Conversely, ARMS is dominated by the presence of specific chromosomal translocations leading to expression of the fused Pax3-Foxo1 and Pax7-Foxo1 factors, that driving in a cell cycle manner the transcription of several genes normally restricted to the embryonal development favor tumor initiation in some muscle precursors. [31] [32] [33] [34] [35] [36] A number of important cellular processes, such as endocytosis, cholesterol homeostasis and signal transduction, Laboratory Investigation (2015) 95, 585-602
Rhabdomyosarcoma (RMS) is a childhood soft tissue sarcoma exhibiting broad expression of skeletal muscle markers, [1] [2] [3] such as Pax7, MyoD, Myogenin, desmin and muscle-specific actin. 4, 5 Cells of origin in RMS may be different muscular and non-muscular cell precursors, [6] [7] [8] such as muscle satellite cells (SCs), [9] [10] [11] and myoblasts 9, 10, [12] [13] [14] or adipocytes, 15 which are responsible of two major histological subtypes known as embryonal (ERMS) and alveolar (ARMS). The most common ERMS variant arises in children usually o5 years on distinct body sites, such as head, neck and genitourinary regions, while ARMS typically arises in the muscular limb extremities of adolescents and is characterized by poorer prognosis. 16 The genomic landscape causative of ERMS is characterized by a number of genetic lesions and/or somatic mutations that deliberately sustain the activity of different receptors, such as IGF1R, FGFR4 and Patched, [17] [18] [19] [20] [21] and related downstream pathways (i.e., RAS/ERK, PI3K/AKT and Sonic Hedgehog signaling). 11, 22 In addition, defects in tumor suppressors (i.e., p53), 23 cell cycle regulatory genes (i.e., N-Myc, Rb1) 21, 24 and structural proteins involved in muscular integrity (i.e., dystrophin, alpha-sarcoglycan and dysferlin) have been reported. [25] [26] [27] [28] [29] [30] Conversely, ARMS is dominated by the presence of specific chromosomal translocations leading to expression of the fused Pax3-Foxo1 and Pax7-Foxo1 factors, that driving in a cell cycle manner the transcription of several genes normally restricted to the embryonal development favor tumor initiation in some muscle precursors. [31] [32] [33] [34] [35] [36] A number of important cellular processes, such as endocytosis, cholesterol homeostasis and signal transduction, takes place in small invaginations of the plasma membrane known as caveolae, 37 specialized microdomains whose morphogenesis and function depend on the complex network established between two protein families known as Caveolins (Cav-1, Cav-2 and Cav-3) [38] [39] [40] and Cavins (Cavin-1, -2, -3 and -4). [41] [42] [43] [44] In particular, deficiency of either Cav-1 45 or Cavin-1 [46] [47] [48] has been reported to cause global loss of caveolae in different tissues. Cav-1 is a scaffolding protein that forms supramolecular complexes anchored to the inner leaflet of the plasma membrane and has been historically reported to be sufficient for de novo formation of caveolae in both caveolaedeficient cells 49 and bacteriae. 50 Cavin-1 was instead recently discovered as a soluble protein stabilizing Cav-1 oligomers and presumably facilitating their membrane insertion underlying the generation of the characteristic caveolar profile. 46, 47, 51 Altered expression levels and gene mutations affecting stability and/or localization of these proteins have been widely reported to be causative of various diseases, ranging from lung diseases and muscular dystrophies to cancer. In RMS, we have previously shown that Cav-1 expression is often associated to a cell status of scarce differentiation. 52, 53 More recently, we have also shown that high Cav-1 protein levels enhance RMS tumor growth and chemoresistance, whereas Cav-1 depletion limits cell proliferation, migration and invasion as well as sensitizes RMS cells to chemotherapy drug-induced apoptosis. 54 Here we have used a combined in silico and in vitro approach to address the question of whether Cavin-1 may be expressed and have a role in RMS. To this purpose, we have used human RMS cell lines as well as primary mouse tumor cultures established from transgenic mouse models faithfully recapitulating the onset and progression of RMS. Our findings unveil that Cavin-1, forming plasma membrane complexes with Cav-1, contributes in sustaining proliferation, migration and anchorage-independent growth of RMS cells.
MATERIALS AND METHODS
All reagents were from Sigma-Aldrich (Milan, Italy), unless otherwise stated. Cell culture materials were purchased from Jet-Biofil (Carlo Erba Reagents-Dasit Group, Cornaredo, Italy).
Microarray Gene Expression Data Analysis
All analyses of microarray gene expression data were performed with the Partek Genomics Suite software version 6.6 (Partek, St Louis, MO, USA). Briefly, the microarray raw data set with the accession number GSE22520 10 deposited in the NCBI Gene Expression Omnibus database were reprocessed by background correction, normalization and summarization of probe intensities using the robust multiarray average analysis to determine the specific hybridizing signal for each probe set. After background correction, the data expression of each probe was corrected for perfect match intensity and was transformed in base-2 logarithm. 55 Quality control was performed by investigating principal component analysis to detect grouping patterns in the samples and to identify the outliers and evaluate whether batch effect significantly affected the data. To detect differentially expressed genes (DEGs) between mouse ARMS/ERMS vs normal muscle samples, a one-way analysis of variance (ANOVA) was performed. To assess significant differences in the gene expression profile in all groups, we selected the genes that had more than a 2.0-fold change (|FC| ≥ 2.0) and P-values o0.05. Multiple testing correction was applied to control the false-discovery rate using the Benjamini-Hochberg procedure. All corrected P-values o0.05 were considered significant.
Histological and Immunofluorescence Analyses
Muscle cryosections were fixed in 4% paraformaldehyde (PFA) on ice. Immunofluorescence analysis of cryosections was performed as previously described. 56 Nuclei were counterstained with Hoechst 33342 (Fluka, Sigma-Aldrich) or with TO-PRO-3 (Invitrogen, Life Technologies, Monza, Italy), and the samples were analyzed under an epifluorescence Zeiss Axioskop 2 Plus microscope (Carl Zeiss, Oberkochen, Germany) or a Leica Leitz DMRB microscope fitted with a DFC300FX camera (Leica, Wetzlar, Germany).
Muscle Satellite Cell Cultures and Tumor Cultures
Primary mouse SCs were prepared from 1-2-week postnatal mouse limbs as described previously. 56 The cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% horse serum (HS) and 5% chick embryo extract (EE). To induce differentiation, the cells were shifted to DMEM supplemented with 5% HS and 1.25% EE for 3-5 days. Human embryonal RD cells were purchased from the European Collection of Cell Cultures. RD cells harbor activating or inactivating RAS and p53 mutations, respectively. [57] [58] [59] Human RD12 and RD18 clonal cell lines, provided by PL Lollini (University of Bologna, Italy), were derived by random cloning of the human RD cell line. 60, 61 Human RH30 cells have a tetraploid karyotype and harbor both the Pax3-Foxo1 signature derived from the t(2;13) translocation 62 and p53-inactivating mutations. 59 The primary mouse ERMS and ARMS cultures, namely, U57810 and U23674, respectively, have been derived from transgenic mice harboring either loss of p53 or concomitant loss of p53 and knock-in of Pax3-Foxo1 in Myf6-positive differentiating myoblasts, respectively. 10, 13 Tumor cells were routinely maintained under standard conditions (37°C and 5% CO 2 in humidified incubator) in a growth medium (GM), composed of highglucose DMEM supplemented with 10% fetal bovine serum (FBS) and 100 μg/ml penicillin-streptomycin antibiotics, in the presence of 1% L-glutamine (only for RH30 and U23674 cells). To induce myodifferentiation, 80% confluent cells were switched to a differentiating medium (DM), composed of DMEM supplemented with 2% HS. Cells received the chemical PD098059 (10 μM, dissolved in dimethylsulfoxide vehicle), a synthetic upstream inhibitor of the RAS/ERK cascade, the pan-phosphatase inhibitor Na 3 VO 4 (20 μM, dissolved in water) and the chemotherapy drug doxorubicin (0.15 ng/ml, dissolved in water).
RNA Isolation and Semi-Quantitative RT-PCR Analysis
Total RNA was isolated using a Tri-reagent kit and treated with DNA-free DNase (Promega, Madison, WI, USA). RNA (2 μg) was reverse transcribed in the presence of 400 Units of Moloney murine leukemia virus reverse transcriptase enzyme (Promega) and the obtained cDNA template was used for PCR analysis using specific forward and reverse primers (250 nM) annealing to both human and mouse sequences. In particular, a 424-bp-long Cavin-1 fragment was amplified homogenates subjected to centrifugation for separating membranous from soluble fractions. Equal amounts of proteins were then western blotted for Cavin-1, Cav-3 and tubulin. Protein bands were quantified by densitometry after normalization with respect to tubulin (n = 3). **Po0.001; ***Po0.0001.
Cavin-1 and Caveolin-1 in rhabdomyosarcoma F Faggi et al with 5′-ATCAAGAAGCTGGAGGTCAACGAG-3′ and 5′-TC TCAGGTTTTCCTTGGTCTTGA-3′ primers, a 103-bp-long Cav-1 fragment with 5′-AACCGCGACCCTAAACACCT-3′ and 5′-CCTTCCAAATGCCGTCAAAA-3′ primers and a 267-bp-long Gapdh fragment with 5′-GGTGCTGAGTATGT CGTGGAGTC-3′ and 5′-GGACTGTGGTCATGAGCCCTT CC-3′ primers.
Plasmids and Transfection
Knockdown constructs were purchased from Tema-Ricerca/ Origene (Castenaso, Italy) in pRS backbone: shCavin-1 #1 (clone TR310045A-TI340173, 5′-ATGATCTACCAGGATG AAGTGAAGCTGCC-3′); shCavin-1 #2 (clone TR310045B-TI340174, 5′-CGCAAGGTCAGCGTCAACGTGAAGACCGT-3′); shCavin-1 #3 (clone TR310045C-TI340175, 5′-CACCTTCC ACGTCAAGAAGATCCGCGAGG-3′). As negative control, pRS-puro vector harboring the off-target sequence (clone TR30012, 5′-GCACTACCAGAGCTAACTCAGATAGTACT -3′) was used. Cav-1 overexpression and knockdown were obtained as previously described in Faggi et al. 54 Cells were stably transfected using Transit-LT1 reagent (Tema-Ricerca) according to the manufacturer's protocol. After antibiotic selection, the experiments produced similar results in all the selected clones.
Antibodies
The following primary antibodies were used: rabbit antiCavin-1 (AbCam, Cambridge, UK, 1:3000 dilution) for immunoblotting and immunofluorescence analyses; rabbit anti-Cavin-1 (ThermoScientific, Waltham, MA, USA) for immunoprecipitation assay; rabbit anti-Cav-1 (Santa Cruz Biotechnology, Dallas, TX, USA, 1:1000 dilution); mouse anti-Cav-1 (Zymed-Life Technologies, Monza, Italy, 1:100 dilution); mouse anti-MHC (Santa Cruz Biotechnology, 1:1000 dilution); mouse anti-Cav-2 (BD, Buccinasco, Italy, 1:1000 dilution); mouse anti-Cav-3 (BD, 1:1000 dilution); mouse anti-total and -phosphorylated ERK1/2 (Tyr204) (Santa Cruz Biotechnology, 1:1000 dilution); mouse antialpha-tubulin (Sigma-Aldrich, 1:10 000 dilution).
Immunoblotting and Immuneprecipitation Analyses
Protein concentration was calculated by Bradford reagent assay. Equal amounts of protein samples were separated by SDS-PAGE under reducing conditions and transferred to polyvinylidine fluoride membranes. Incubation with specific primary antibodies was followed by horseradish peroxidaseconjugated secondary antibodies, including goat anti-mouse IgG (Santa Cruz Biotechnology) and donkey anti-rabbit IgG from Thermo Scientific-Pierce, Erembodegem, Belgium), and the resulting immune complexes were visualized using enhanced chemiluminescence reagent (GeneSpin, Milan, Italy). Immune-reactive bands were quantified using densitometric analyses (Software Gel Pro Analyzer, version 4). For detection of Cavin-1, myosin heavy chain (MHC) and tubulin, total homogenates were prepared by harvesting the cells in cold RIPA lysis buffer, composed of 20 mM Tris-HCl (pH 7.6), 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM NaCl, and a cocktail of protease inhibitors (Roche, Monza, Italy) plus phosphatase inhibitors (1 mM Na 3 VO 4 and 4 mM NaF). Total homogenates were then centrifuged at 12 000 g for 10 min at 4°C. For detection of Caveolins, the Triton-insoluble membranous fractions were obtained by harvesting the cells in a cold Triton buffer, composed of 10 mM Tris-HCl (pH 8.0), 1% Triton X-100, 5 mM EDTA, 150 mM NaCl and a cocktail of protease inhibitors plus phosphatase inhibitors, followed by centrifugation (15 000 g for 15 min at 4°C). For immunoprecipitation analysis, the cells were lysed in a buffer composed of 50 mM Tris-HCl buffer (pH 7.4), containing 150 mM NaCl, 1% Triton X-100 and a cocktail of protease and phosphatase inhibitors, followed by incubation for 20 min at 4°C. After centrifugation (10 min, 11 500 g at 4°C), supernatants were pre-cleared with protein GSepharose (20 μl/sample, GE Healthcare, Fairfield, CT, USA) for 1 h. Cell extracts (1 mg aliquots) were incubated overnight with bland agitation at 4°C with rabbit polyclonal anti-Cav-1 Cavin-1 and Caveolin-1 in rhabdomyosarcoma F Faggi et al (5 μl/sample, Santa Cruz Biotechnology) or rabbit anti-Cavin-1 (10 μl/sample, ThermoScientific). Immune complexes were then recovered on protein G-Sepharose (1 h with bland agitation at 4°C), centrifuged (1 min, 14 000 g) and washed four times with lysis buffer and twice with the same buffer without Triton X-100. Proteins were then analyzed on nonreducing SDS-12% PAGE followed by immunoblotting with anti-Cavin-1 and anti-Cav-1 antibodies. The enhanced chemiluminescence technique (Genespin) was used for detection. As positive control, 30 μg of total homogenates was loaded, whereas 30 μg of pre-cleared sample was loaded as negative control. Human RD cells cultured in GM for 72 h were fixed, permeabilized and immunostained with antibodies against Cavin-1, Cav-1 and Cav-2 followed by anti-rabbit and anti-mouse Cy3, respectively. Alternatively, confluent RD cells were cultured in DM for 72 h and then fixed, permeabilized and immunostained with antibodies against Cavin-1 and Cav-3 followed by anti-rabbit Alexa488 and anti-mouse Cy3, respectively. Chemotaxis Assay Cells (25 × 10 3 in 50 μl of DMEM with 5% FBS) were seeded in the upper compartment of a Boyden chamber, containing gelatin-coated PVP-free polycarbonate filters (8 μm pore size, Costar-Corning, Tewksbury, MA, USA) and DMEM with 10% FBS in the lower compartment. As a negative control, 1% FBS medium was used. After 5 h of incubation at 37°C, cells migrated to the lower side of the filter were stained with Diff-Quik (Dade-Behring, GE Healthcare). Five random fields were counted for each triplicate sample.
Cell Viability Assay
The lysosomal accumulation of neutral red dye was used to evaluate the percentage of viable cells. 63, 64 Briefly, the cells were seeded into 96-well plates (at a density of 1.5 × 10 3 cells). After 24 h, cells received doxorubicin (0.15 ng/ml) for 48 h, before incubation for 2 h with neutral red dye (40 μg/ml) dissolved in DMEM with 5% FBS. Cells were then washed with PBS and 100 μl of elution medium (50% ethanol and 1% acetic acid), followed by gentle shaking for 10 min so that complete dissolution was achieved. Absorbance was then measured by reading the plate at 540 nm emission wavelength. Results are presented as percentage of control values. Images of cell viability assays reflect representative results of at least three independent experiments.
Soft Agar Colony Formation Assay
Control RD cells and clones (overCav-1, shCav-1 and shCavin-1) were suspended in 1 ml of medium containing 0.3% agar and applied onto 2 ml of presolidified 0.6% agar plus 20% FBS in six-well plates (10 × 10 5 cells/well). After 1-2 and 3 weeks of incubation, colonies were observed under a phase contrast microscope, photographed and counted. The results were expressed as the mean ± s.d. of triplicate counts within the same experiment.
Statistical Analysis
The differences between the groups were analyzed by unpaired Student's t-tests and one-way ANOVA test (with Dunnet's post test), using Prism 4 software for Windows (GraphPad Software). Statements of significance were based on a P-value of o0.05. (Figure 1a) . In addition, Cavin-1 staining was localized in mononucleated cell elements surrounding the myofibers as well as at the plasmalemma of myofibers positive for MHC ( Figure 1a) . As the pool of mononucleated cells residing interposed among the myofibers may comprise several cell elements of different origin, including muscle SCs, fibroadipogenic progenitors and mesenchymal stem cells, 65 we decided to address the question of whether Cavin-1 was specifically present in SCs. To this purpose, the protein levels of Cavin-1 were analyzed in ex vitro experiments using SCs isolated from mouse skeletal muscle. Immunoblotting analysis carried out on membranous and soluble cell fractions showed the presence of Cavin-1 in proliferating SCs as well as its incremented expression during the myogenic differentiation, which was characterized by raised levels of Cav-3 ( Figure 1b) . Given the presence of Cavin-1 in skeletal muscle, we decided to evaluate whether Cavin-1 might be present in RMS, further evaluating the levels of Caveolins because of their close relationship. 46 To this purpose, we employed an in silico approach taking advantage of microarray data that have been previously generated by the analysis of RMS tumors arisen in mouse models with specific genetic alterations. 10 As shown by dot plot graphs (Figure 2a) , the relative levels of Cavin-1 and Caveolins, as detected in ARMS (n = 14) and ERMS (n = 7) tumors, were similar to those found in skeletal muscle samples (n = 4) ( Figure 2a) . As represented by the Venn diagram, this in silico analysis allowed to identify 3136 and 2322 DEGs in ARMS and ERMS tumors with respect to skeletal muscle (fold-change ≥ 2, corrected P ≤ 0.05), respectively (Figure 2b ). The analysis essentially indicated that Cavin-1, Cav-1 and Cav-2 were expressed in a similar manner in tumors and skeletal muscle, while only Cav-3 fell into the subset of DEGs that were significantly downregulated in ARMS compared with skeletal muscle (Figure 2b ). We then Cavin-1 and Caveolin-1 in rhabdomyosarcoma F Faggi et al analyzed the protein expression by immunoblotting using different RMS lines, including two primary tumor cultures established from RMS-bearing transgenic mice 10 and four human RMS cell lines (see Materials and Methods for the genetic background characterizing each line). In mouse and human cells, the molecular weight of Cavin-1 protein band was~43 and 50 kDa, respectively (Figure 3a) . In particular, Cavin-1 was always recognized in concomitance with Cav-1 and Cav-2 in cells cultured in GM, while stimulating a variable degree of myogenic differentiation by culturing the cells in DM for 3 days led to downregulation of Cavin-1, Cav-1 and Cav-2 followed by upregulation of Cav-3 and MHC levels ( Figure 3a) . By immunofluorescence analysis we observed that Cavin-1 partially colocalized with either Cav-1 or Cav-2 during cell proliferation, as shown in RD cells (Figure 3b, upper panels) . Conversely, Cavin-1 and Cav-3 did not colocalize, as observed during myodifferentiation of RD cells (Figure 3b , bottom panels). Analogous results were also observed in RH30 cells (not shown).
Results

Cavin
-1 is Expressed in Skeletal Muscle as well as in Myogenic RMS Tumors Immunofluorescence experiments were performed to analyze Cavin-1 distribution in mouse skeletal muscle. In cryosections from tibialis anterior muscle, Cavin-1 staining was expectedly found labeling endothelial cells in the blood vessels (BVs)
Cavin-1, Cav-1 and Cav-2 Downregulation is Specifically Related to Myogenic Differentiation of RMS Cells
To understand whether Cavin-1, Cav-1 and Cav-2 downregulation might be specifically related to the block of cell cycle rather than differentiation, we treated proliferating RD and RH30 cells with PD098059 or Na 3 VO 4 , which were reported to affect RMS cell proliferation via inhibition of the ERK signaling and phosphatase activity, respectively. [66] [67] [68] As determined by Crystal violet assay, either treatment was effective in reducing cell proliferation in comparison to vehicle-treated cells (Figure 4a ), but without affecting the protein levels of Cavin-1, Cav-1 and Cav-2, as shown by immunoblotting and relative densitometric analysis (Figure 4b ). In these conditions, the inhibition of proliferation was not accompanied by concomitant differentiation, as the expression levels of Cav-3 and MHC were always undetectable (Figure 4b ). Conversely, forcing the myogenic differentiation of RD cells by co-treatment with DM and PD098059 led to reduction in Cavin-1, Cav-1 and Cav-2 protein levels followed by increased levels of Cav-3 and MHC (Figure 4c ). These data suggest that concomitant presence of Cavin-1, Cav-1 and Cav-2 is mainly predictive of RMS cell growth, whereas downregulation of their protein levels seems to be a consequence of the differentiation program.
Cavin-1 Interacts with Cav-1 at the Plasma Membrane of ERMS and ARMS Cells
Confocal microscopy analysis was used to evaluate the subcellular localization of Cavin-1 and Cav-1 in RD cells. As shown in Figure 5a (left panels), Cavin-1 exhibited a broad cellular distribution, ranging from nuclei (highlighted via three-dimensional reconstruction images in the right panels) and cytosol to plasma membrane, whereas Cav-1 was more localized at the plasma membrane and to a lesser extent in the cytosol. Colocalization of Cavin-1 with Cav-1 was specifically detectable at the plasma membrane, as shown in merged images (yellow color) (Figure 5b) . Moreover, Cav-1 and Figure 5 Continued.
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Cavin-1 partially colocalized also at the perinuclear regions presumably corresponding to Golgi apparatus, where both nascent proteins are synthesized. 43 To address the question of whether Cavin-1 and Cav-1 might specifically interact, we also carried out immunoprecipitation of endogenous Cav-1 or Cavin-1 followed by immunoblotting against Cavin-1 and/or Cav-1 using the cell extracts obtained from four human and mouse RMS cell lines. These experiments clearly show that Cavin-1 and Cav-1 physically interact, especially during cell growth (Figure 5c ).
Overall, these data suggest that Cavin-1 and Cav-1 form protein complexes at the plasma membrane of proliferating RMS cells.
Cavin-1 Knockdown Decreases Cell Proliferation and Migration in the Embryonal RD and Alveolar RH30 Cell Lines
To determine whether loss of Cavin-1 might affect the behavior of RMS cells, we knocked down Cavin-1 expression in human RD and RH30 cells. To this purpose, we selected different clones in which the transcript and protein levels of Cavin-1 were downregulated by stable delivery of shCavin-1 vectors in comparison to shOFF target (i.e., shOT) constructs, as shown by semiquantitative PCR and immunoblotting (Figure 6a) . By immunofluorescence analysis, Cavin-1 labeling was consistently reduced at the plasma membrane and in the cytosol of shCavin-1 clones in comparison to shOT cells, with a residual signal remaining barely detectable in the nuclei of RD cells (Figure 6b ).
As Cavin-1 depletion has been reported to trigger Cav-1 mislocalization followed by protein degradation, 69 we evaluated the expression and localization of Cav-1 in shCavin-1 clones. In both RD and RH30 lines, there was no significant difference in Cav-1 transcript and protein levels between shCavin-1 and control shOT clones, as detected via semiquantitative PCR and immunoblotting (Figure 6a ). Immunofluorescence analysis showed that the loss of Cavin-1 triggered an intracellular accumulation of Cav-1 in RD cells, which gave rise to a marked staining at the perinuclear regions (Figure 6b, upper panels) . In addition, shCavin-1 clones in RD cells exhibited a residual nuclear staining (Figure 6b) . Indeed, nuclear proteins are more resistant to knockdown mediated by shRNA because of the reduced availability of RNAi cellular machinery into the nucleus. 70 In contrast, Cavin-1 downregulation in RH30 cells did not affect the subcellular localization of Cav-1 (Figure 6b , bottom panels). We next assayed the cell proliferation, migration and chemoresistance of the different clones by means of the Crystal violet, Boyden chamber and Neutral Red assays, respectively. We observed that shCavin-1 clones exhibited a significant impairment of cell proliferation and migration in comparison to shOT cells, in both RD and RH30 lines (Figure 6c) . Conversely, the loss of Cavin-1 did not affect the chemoresistance to doxorubicin in comparison to shOT cells (Figure 6c) .
Collectively, these data indicate that Cavin-1 depletion significantly impairs the proliferation and migration, but not chemoresistance, of the embryonal RD and alveolar RH30 cells.
The Modulation of Cav-1 Expression Impacts the Cavin-1 Levels and the Cancerous Behavior of the RD Cell Line
We have recently demonstrated that Cav-1 overexpression favors RMS growth, migration and chemoresistance, whereas Cav-1 depletion inhibits cell growth and migration, further sensitizing RMS cells to cell apoptosis induced by chemotherapy drugs. 54 Hence, we used specific RD clones in which Cav-1 has been overexpressed or knocked down (overCav-1 and shCav-1 clones, respectively) to analyze the effects on Cavin-1 expression and cellular localization. Cav-1 overexpression or knockdown yielded increased or decreased protein levels of Cavin-1, respectively, as shown via immunoblotting (Figure 7a) . Furthermore, immunoprecipitation experiments clearly showed that the amount of Cavin-1 and Cav-1 complexes was increased in Cav-1-overexpressing RD cells (Figure 7b ). Immunofluorescence analysis showed that Cav-1 overexpression, yielding an increased Cav-1 staining at the plasma membrane as well as in intracellular perinuclear regions, resulted in an increased and diffused intracellular Cavin-1 and Caveolin-1 in rhabdomyosarcoma F Faggi et al Cavin-1 and Caveolin-1 in rhabdomyosarcoma F Faggi et al Cavin-1 staining (Figure 7c) . Conversely, Cav-1 depletion led to almost complete loss of Cavin-1 staining (Figure 7c) .
Taken together, these data suggest that the levels of Cav-1 seem to influence those of Cavin-1 and not vice versa, at least in RD cells.
Cavin-1 and Cav-1 are Both Required to Confer Anchorage-Independent Cell Growth in the RD Line Normal cells require a solid substratum to proliferate, whereas malignant cells gain the ability to grow regardless of their attachment status. In this regard, the cell anchorageindependent growth represents an important hallmark predictive of cellular transformation.
To address the question of whether Cavin-1 and Cav-1 may contribute to anchorage-independent cell growth, we performed a soft agar colony formation assay using RD cells. Either loss of Cavin-1 or Cav-1 was detrimental to anchorageindependent cell growth, as shCavin-1 clones formed fewer colonies (Figure 8a ), whereas shCav-1 clones had completely lost the ability to form colonies in comparison to control shOT cells (Figure 8b) . Conversely, Cav-1-overexpressing cells more quickly formed highly dense colonies in comparison to mock cells (Figure 8c ).
These data indicate that loss of either Cavin-1 or Cav-1 impairs the ability of RD cells to grow in an anchorageindependent manner, whereas the gain of Cav-1 and the concomitant increase of Cavin-1 correlated with an incremented anchorage-independent cell growth.
DISCUSSION
Cavin-1, also known as polymerase transcription released factor, is a soluble protein that was originally identified as a nuclear factor cooperating with RNA polymerase I during the transcription process 71, 72 as well as interacting with the BFCOL1 (binding factor of a type-I collagen promoter) zincfinger transcription factor. 73 Since then, Cavin-1 was also identified in lipid rafts, 74 especially in adipocytes, [75] [76] [77] [78] where it has an active role during hormone-sensitive lipolysis. 77, 78 Over the past years some works have unveiled that this versatile protein even specifically cooperates with Cav-1 in the morphogenesis of caveolae, [74] [75] [76] [77] [78] specialized microdomains of the plasma membrane that in several cell types represent the primary sites of important processes such as the endocytosis and signal transduction. 37 In particular, Cavin-1 seems to have a pivotal role as protein cargo facilitating the transport of Cav-1 oligomers from the Golgi compartments toward the plasma membrane, whereby their insertion into the inner membranous leaflet actively participates in the establishment of caveolar domains by triggering the membrane curvature. Consistent with this, loss of either Cavin-1 or Cav-1 in mouse models triggers the flattening of caveolar domains and reflects in partially overlapping phenotypes characterized by the onset of different diseases. For example, deficiency of Cavin-1 in skeletal muscle has been associated with human lipodystrophy, muscular dystrophy and cardiac dysfunction. [79] [80] [81] [82] [83] [84] In accordance, mice lacking Cavin-1 exhibit a lipodystrophic phenotype 48 as well as an altered metabolic flux among multiple tissues, which suggests a role of Cavin-1 in the coordination of peripheral glucose and fatty-acid storage and utilization. 85 Figure 8 Analysis of the anchorage-independent cell growth in engineered RD cells. A soft agar assay was performed to evaluate the ability of RD cells to grow in a substrate-independent manner after knockdown of Cavin-1 (a) or Cav-1 (b) and overexpression of Cav-1 (c). Values obtained by quantification of the colony numbers are the means ± s.d. of at least three independent experiments. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001.
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Cavin-1 has been also reported to have a pivotal role for the initiation of membrane repair upon injury in skeletal muscle. 86 In mouse skeletal muscle we recognized Cavin-1 localizing in the mononucleated cell elements (i.e., SCs) surrounding the myofibers as well as at the plasmalemma of differentiated myofibers. During the ex vitro experiments ideally resembling the process of muscle regeneration occurring in vivo, when upon injury SCs escape quiescence and proliferate toward the damaged site to differentiate into newly formed myofibers, we observed increased protein levels of Cavin-1 in both the cytosolic and membranous fractions of SCs committed toward differentiation, therefore suggesting that Cavin-1 could be especially required for skeletal muscle formation during embryogenesis and muscle repair in the adult life.
Skeletal muscle also represents one of the major source of cell precursors that, in the presence of genetic lesions, may undertake a tumorigenic route resulting in the development of RMS, the most frequent soft tissue tumor of childhood. [1] [2] [3] In this context, we found Cavin-1 expression to be always matching with Cav-1 and Cav-2 in proliferating human lines and mouse primary cultures established from tumors occurring in transgenic mice that faithfully recapitulate the appearance and progress of RMS. 10, 13 We detected a slight difference in the molecular weight of human and mouse Cavin-1 forms (i.e., 43.5 vs 50 kDa, respectively), suggesting the potential occurrence of posttranslational modifications. In this regard, one N-terminal acetylation site and four phosphorylation sites localized to Ser-36, Ser-40, Ser-365 and Ser-366 have been mapped along Cavin-1 sequence. 76 Cavin-1 exhibited a broad subcellular localization in both human and mouse RMS cultures, ranging from nuclei and cytosol to plasma membrane. Unlike the muscle cells, the defective differentiation program observed in cancerous RMS cell elements 2 was characterized by downregulation of Cavin-1, Cav-1 and Cav-2 expression.
In different types of cancer, including breast cancer, 87 lung cancer 88 and prostate cancer, 89 the role of Cavin-1 is gradually assuming significant proportions and recent lines of evidence have put forward its dual behavior. For example, Cavin-1 was reported to decrease the malignant behavior of prostate PC3 cancer cells through different mechanisms, [89] [90] [91] [92] [93] although being essential for the tumor-promoting effect of Cav-1 in pancreatic cancer 94 and for multidrug resistance in breast cancer lines. 95 By analogy, even the role of Cav-1 in cancer appears to be ambiguous, because Cav-1 may behave as either a tumor suppressor or oncopromoter depending on the type of tumor. [96] [97] [98] [99] [100] [101] Our data argue for an important role of Cavin-1 as essential partner of Cav-1 in RMS progression, as we clearly observed that loss of either Cavin-1 or Cav-1 was sufficient to impair cell proliferation, migration and anchorage-independent cell growth, a characteristic predictive of cell transformation in vitro and in vivo. Consistent with this, we also found that an incremental expression of Cavin-1 in RD cells, as causally obtained upon Cav-1 overexpression, led to a very aggressive cell behavior, which was characterized by a remarkable anchorage-independent cell growth. Hence, the plasma membrane interaction of Cavin-1 and Cav-1 may represent an important initiation signal for specific downstream pathways underlying the proliferation, migration and survival of RMS cells. In this context, the formation of Cavin-1 and Cav-1 complexes has been shown to promote a p53-dependent premature senescence in fibroblasts exposed to oxidative stress 102, 103 and to regulate the internalization of IGF1R in human Hacat cells. 104, 105 Hence, it will be important to assess whether Cavin-1 and Cav-1 complexes may influence specific targets, such as p53 and IGF1R, that play a central role in RMS progression. 17, 106 It is also of interest that we found Cavin-1 colocalizing with Cav-2 in proliferating RMS cells. Although we primarily focused on the interaction between Cavin-1 and Cav-1, a potential involvement of Cavin-1 and Cav-2 complexes in RMS cell survival and cancerous behavior cannot be ruled out.
Overall, the data of this work indicate Cavin-1 and Cav-1 as potential molecular targets for counteracting the proliferation, migration and clonogenic potential of RMS cells. 
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